CORONA Trial

Jump to navigation Jump to search

High Density Lipoprotein Microchapters

Home

Patient information

Overview

Historical Perspective

Classification

Physiology

Pathophysiology

Causes

Low HDL
High HDL

Epidemiology and Demographics

Screening

Natural History, Complications and Prognosis

Diagnosis

HDL Laboratory Test

Treatment

Medical Therapy

Prevention

Future or Investigational Therapies

Clinical Trials

Landmark Trials

List of All Trials

Case Studies

Case #1

CORONA Trial On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of CORONA Trial

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on CORONA Trial

CDC on CORONA Trial

CORONA Trial in the news

Blogs on CORONA Trial

Directions to Hospitals Treating High density lipoprotein

Risk calculators and risk factors for CORONA Trial

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Click here to download slides for CORONA Trial.

Objective

To study the effects of rosuvastatin 10 mg daily in patients with congestive heart failure.

Methods

Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) was a double-blinded, randomized, placebo controlled trial wherein 5011 patients with congestive heart failure NYHA Class II, III or IV ischemic, systolic heart failure were enrolled and randomly assigned to treatment with either 10 mg rosuvastatin daily or placebo. The primary outcome was death from cardiovascular causes, non-fatal MI or non-fatal stroke.

Results

Compared to placebo, rosuvastatin reduced serum LDL levels and raised HDL and triglyceride levels. However, there was no significant reduction in mortality rates from cardiovascular causes, coronary events and all-cause mortality.[1][2][3][4]

References

  1. Kjekshus J, Apetrei E, Barrios V; et al. (2007). "Rosuvastatin in older patients with systolic heart failure". The New England Journal of Medicine. 357 (22): 2248–61. doi:10.1056/NEJMoa0706201. PMID 17984166. Unknown parameter |month= ignored (help)
  2. van der Harst P, Slart RH, Tio RA; et al. (2010). "Effects of rosuvastatin on coronary flow reserve and metabolic mismatch in patients with heart failure (from the CORONA Study)". The American Journal of Cardiology. 105 (4): 517–21. doi:10.1016/j.amjcard.2009.10.021. PMID 20152247. Unknown parameter |month= ignored (help)
  3. Lorgelly PK, Briggs AH, Wedel H; et al. (2010). "An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial". European Journal of Heart Failure. 12 (1): 66–74. doi:10.1093/eurjhf/hfp172. PMC 2796144. PMID 20023047. Unknown parameter |month= ignored (help)
  4. McMurray JJ, Kjekshus J, Gullestad L; et al. (2009). "Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis". Circulation. 120 (22): 2188–96. doi:10.1161/CIRCULATIONAHA.109.849117. PMID 19917888. Unknown parameter |month= ignored (help)